News

Call for Abstracts to Present at MHSRS 2021

The call for abstracts to present a poster at this year’s Military Health System Research Symposium (MHSRS) is now open through March 31. They are planning for this year’s conference to be in person. The dates are pending, but usually are in mid- to late-August in Orlando, FL. G2G account managers will reach out separately and in your next check-in call re: assisting with a submission. Details below.

NOTE: DoD-sponsored SARS CoV-2 (COVID-19) related research will be highlighted in dedicated 2021 MHSRS breakout sessions. Oral presentations at these sessions will be by invitation only.

* The Call for Abstracts will be for posters only. COVID-19 related research abstracts submitted to sessions other that those that are focused on COVID-19 will be re-directed to the COVID-19 session leads for poster consideration.

* For 2021, a special MHSRS award category for COVID-19 research will be offered for individuals and teams.

2021 MHSRS Call for Abstracts
February 17, 2021 to March 31, 2021
The deadline will not be extended past 31 March 2021.

How to Submit a 2021 Abstract
(1) Complete the abstract submission form, (2) upload a CV, (3) upload a signed Conflict of Interest (COI) form

The abstract should be no more than 8000 characters in length. There are no format or font restrictions. No embedded tables, pictures, or videos will be accepted. Have the presenter CV and signed COI form in pdf format ready to upload when you initiate abstract submission to facilitate the submission process.

Link to submit and Abstract: https://mhsrs.amedd.army.mil/SitePages/Submit-an-Abstract.aspx

Recent News

06/29/2022

Bio-plastics startup wins Lighthouse Labs pitch contest

Charlottsville, VA (Virginia Business) – While pitching to the sharks, entrepreneur Alec Brewer told them, “I do have white powder in my pocket,” before quickly clarifying that it wasn’t an illicit substance: “It’s PHB! It’s PHB!” The co-founder and CEO of Charlottesville-based biodegradable plastics manufacturer Ourobio, Brewer explained that his company makes PHB, or polyhydroxybutyrate,

06/26/2022

USA FDA Grants Fast Track Designation to ReAlta Life Sciences’ Lead Compound RLS-0071

ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE). RLS-0071 is the Company’s lead dual

06/20/2022

Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence

New patent covers the use of the full genetic panel measuring all five genetic biomarkers CHARLOTTESVILLE, Va., — Adial Pharmaceuticals, Inc. (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,351,154 was issued on June 7, 2022, by